These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 16423879)

  • 21. Differential fibroblast growth factor 8 (FGF8)-mediated autoregulation of its cognate receptors, Fgfr1 and Fgfr3, in neuronal cell lines.
    Mott NN; Chung WC; Tsai PS; Pak TR
    PLoS One; 2010 Apr; 5(4):e10143. PubMed ID: 20405041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.
    Powers GL; Ellison-Zelski SJ; Casa AJ; Lee AV; Alarid ET
    Oncogene; 2010 Mar; 29(10):1509-18. PubMed ID: 19946334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases.
    Beck IM; Vanden Berghe W; Vermeulen L; Yamamoto KR; Haegeman G; De Bosscher K
    Endocr Rev; 2009 Dec; 30(7):830-82. PubMed ID: 19890091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The interaction between thymine DNA glycosylase and nuclear receptor coactivator 3 is required for the transcriptional activation of nuclear hormone receptors.
    Chiang S; Burch T; Van Domselaar G; Dick K; Radziwon A; Brusnyk C; Edwards MR; Piper J; Cutts T; Cao J; Li X; He R
    Mol Cell Biochem; 2010 Jan; 333(1-2):221-32. PubMed ID: 19652917
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processes.
    Arendt LM; Evans LC; Rugowski DE; Garcia-Barchino MJ; Rui H; Schuler LA
    J Endocrinol; 2009 Oct; 203(1):99-110. PubMed ID: 19635758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulating estrogen receptor-related receptor-alpha activity inhibits cell proliferation.
    Bianco S; Lanvin O; Tribollet V; Macari C; North S; Vanacker JM
    J Biol Chem; 2009 Aug; 284(35):23286-92. PubMed ID: 19546226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generation of dopamine neurons with improved cell survival and phenotype maintenance using a degradation-resistant nurr1 mutant.
    Jo AY; Kim MY; Lee HS; Rhee YH; Lee JE; Baek KH; Park CH; Koh HC; Shin I; Lee YS; Lee SH
    Stem Cells; 2009 Sep; 27(9):2238-46. PubMed ID: 19522012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. OTU Domain-containing ubiquitin aldehyde-binding protein 1 (OTUB1) deubiquitinates estrogen receptor (ER) alpha and affects ERalpha transcriptional activity.
    Stanišić V; Malovannaya A; Qin J; Lonard DM; O'Malley BW
    J Biol Chem; 2009 Jun; 284(24):16135-16145. PubMed ID: 19383985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HACE1: A novel repressor of RAR transcriptional activity.
    Zhao J; Zhang Z; Vucetic Z; Soprano KJ; Soprano DR
    J Cell Biochem; 2009 Jun; 107(3):482-93. PubMed ID: 19350571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estradiol and tamoxifen mediate rescue of the dominant-negative effects of estrogen response element-binding protein in vivo and in vitro.
    Chen H; Clemens TL; Hewison M; Adams JS
    Endocrinology; 2009 May; 150(5):2429-35. PubMed ID: 19106221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular mechanisms regulating glucocorticoid sensitivity and resistance.
    Gross KL; Lu NZ; Cidlowski JA
    Mol Cell Endocrinol; 2009 Mar; 300(1-2):7-16. PubMed ID: 19000736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The orphan receptor ERRalpha interferes with steroid signaling.
    Teyssier C; Bianco S; Lanvin O; Vanacker JM
    Nucleic Acids Res; 2008 Sep; 36(16):5350-61. PubMed ID: 18697814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. E6-associated protein (E6-AP) is a dual function coactivator of steroid hormone receptors.
    Ramamoorthy S; Nawaz Z
    Nucl Recept Signal; 2008 Apr; 6():e006. PubMed ID: 18432313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nuclear receptors CAR and PXR in the regulation of hepatic metabolism.
    Tien ES; Negishi M
    Xenobiotica; 2006; 36(10-11):1152-63. PubMed ID: 17118922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lives and times of nuclear receptors.
    Alarid ET
    Mol Endocrinol; 2006 Sep; 20(9):1972-81. PubMed ID: 16423879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Linking the ubiquitin-proteasome pathway to chromatin remodeling/modification by nuclear receptors.
    Kinyamu HK; Chen J; Archer TK
    J Mol Endocrinol; 2005 Apr; 34(2):281-97. PubMed ID: 15821097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rush hour at the promoter: how the ubiquitin-proteasome pathway polices the traffic flow of nuclear receptor-dependent transcription.
    Dennis AP; O'Malley BW
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):139-51. PubMed ID: 15860256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging roles of the 26S proteasome in nuclear hormone receptor-regulated transcription.
    Keppler BR; Archer TK; Kinyamu HK
    Biochim Biophys Acta; 2011 Feb; 1809(2):109-18. PubMed ID: 20728592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expanding functional diversity of the coactivators.
    Lonard DM; O'Malley BW
    Trends Biochem Sci; 2005 Mar; 30(3):126-32. PubMed ID: 15752984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ligand binding and nuclear receptor evolution.
    Escriva H; Delaunay F; Laudet V
    Bioessays; 2000 Aug; 22(8):717-27. PubMed ID: 10918302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.